Mitelos started its journey in the market by the end of 2016 with the commercialisation of its first product. A little over 5 years later Mitelos has just reached  sales of 2 million units of their ear health franchise comprising two  solutions-based medical devices. To date, Mitelos ear care products are Otiblock® for the treatment and prevention of earwax impaction and Otidry-MD® for the prevention of acute otitis externa (“swimmer's ear”).

In these years and, also thanks to the help of commercial partners and stakeholders, Mitelos has accumulated a great deal of experience that has allowed them to improve processes and products, and this will allow them to take on new challenges from a solid base.

A common feature of both products is that before starting their development Mitelos studied the physiology of the outer ear and the requirements necessary to be respectful of it. In addition, in collaboration with engineers from the Polytechnic University of Valencia who designed an "artificial” ear for Mitelos, they have studied the spray dynamics in relation to the external auditory canal.

Mitelos’ products are currently available to doctors, pharmacists, and patients in 15 countries on 5 continents, and estimate that before the end of 2022 they will be available in nearly 20 countries.